Hyperhidrosis Treatment Market Report 2026

The hyperhidrosis treatment market size has grown strongly in recent years. It will grow from $1.67 billion in 2025 to $1.77 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to increased awareness of hyperhidrosis as a medical condition, widespread use of aluminum chloride topical treatments, growing dermatology clinic availability, rising social discomfort linked to excessive sweating, established surgical intervention practices.

The hyperhidrosis treatment market size is expected to see strong growth in the next few years. It will grow to $2.29 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to increasing demand for non-surgical treatments, technological advancements in laser therapies, rising adoption of botulinum toxin a injections, growth in home-use medical devices, expanding healthcare access in emerging markets. Major trends in the forecast period include growing adoption of botulinum toxin treatments, increasing preference for minimally invasive procedures, rising demand for home-based iontophoresis devices, expansion of laser and energy-based therapies, higher focus on quality-of-life improvement therapies.

The increasing prevalence of diabetes mellitus is expected to drive the growth of the hyperhidrosis treatment market going forward. Diabetes mellitus is a condition in which the body either does not produce enough insulin or cannot use it effectively, leading to elevated blood sugar (glucose) levels. This condition can damage the nerves that regulate sweat glands, resulting in excessive sweating or hyperhidrosis. Diabetes may also interfere with the body’s ability to maintain a stable temperature and produce an appropriate amount of sweat for cooling. For instance, in June 2023, the Institute for Health Metrics and Evaluation, a US-based public health research institute, reported that over half a billion people worldwide were living with diabetes. This number is projected to more than double, reaching 1.3 billion by 2050. Therefore, the rising prevalence of diabetes mellitus is driving the hyperhidrosis treatment market.

Major companies in the hyperhidrosis treatment market are focusing on safer, non-invasive therapies with enhanced efficacy, developing topical and targeted drug formulations, and conducting clinical trials to provide longer-lasting symptom relief with fewer side effects. For example, in March 2025, a newly approved topical therapy, sofpironium gel, represented a significant advancement in treating primary axillary hyperhidrosis, which affects millions in the U.S. The gel is a retrometabolic drug that targets M3 muscarinic receptors in sweat glands, reducing sweating while minimizing systemic side effects due to rapid metabolism. Phase 3 trials showed noticeable symptom improvement within one week, with effects lasting throughout the six-week study. Compared to existing topical anticholinergics, sofpironium demonstrated a superior safety profile and fewer adverse reactions. Long-term data also confirmed sustained efficacy and tolerability, making it an effective, non-invasive option for patients dissatisfied with current treatments.

In June 2023, miraDry Inc., a US-based company specializing in non-invasive hyperhidrosis treatment, partnered with the International Hyperhidrosis Society (IHhS) to enhance hyperhidrosis therapies and improve patient outcomes. The International Hyperhidrosis Society is a US-based non-profit organization that serves millions of patients affected by excessive sweating.

Major companies operating in the hyperhidrosis treatment market are Pfizer Inc., AbbVie Inc., Sanofi S.A., AstraZeneca Plc, GSK plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., Cynosure LLC, Ipsen SA, Galderma S.A., Merz Pharma GmbH & Co. KGaA, Daewoong Pharmaceutical Co. Ltd., Supernus Pharmaceuticals Inc, Kaken Pharmaceutical Co Ltd, Avanor Healthcare Ltd., HUGEL Inc., Evolus Inc., Revance Therapeutics Inc., Dermira Inc., Sesderma SL, Miramar Labs Inc., Dermavant Sciences Inc., Theravida Inc., SweatBlock, Brickell Biotech Inc., Fresh Tracks Therapeutics Inc., Advin Health Care Inc, Dermadry Laboratories Inc., Ulthera Inc., Dermata Therapeutics Inc.

North America was the largest region in the hyperhidrosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hyperhidrosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hyperhidrosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the hyperhidrosis treatment market by raising costs for imported medical devices, botulinum toxin formulations, and laser-based equipment used in advanced therapies. These impacts are most significant for device-intensive treatments in hospitals and ambulatory surgical centers, particularly in regions reliant on international suppliers such as Asia-Pacific and Europe. However, tariffs are also encouraging local manufacturing, domestic sourcing, and innovation in cost-effective treatment alternatives, supporting long-term market resilience.

The hyperhidrosis treatment market research report is one of a series of new reports that provides hyperhidrosis treatment market statistics, including hyperhidrosis treatment industry global market size, regional shares, competitors with a hyperhidrosis treatment market share, detailed hyperhidrosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the hyperhidrosis treatment industry. This hyperhidrosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hyperhidrosis is a medical condition characterized by excessive sweat production that exceeds the body’s needs for temperature regulation. It can affect various areas of the body, including the underarms, palms, and soles of the feet. Hyperhidrosis treatment refers to medical interventions and therapies designed to manage or alleviate the symptoms of this condition. The goal of treatment is to improve the quality of life for affected individuals by reducing or controlling excessive sweating.

The main types of hyperhidrosis treatments include topical therapies, surgical procedures, botulinum toxin A, iontophoresis, laser treatments, and others. Topical treatments involve applying therapeutic agents directly to the skin. These treatments are administered via multiple routes, such as oral or injectable, and are used for various forms of hyperhidrosis, including axillary, palmar, and plantar types. They are distributed through a range of channels, including hospitals, ambulatory surgical centers, retail pharmacies, and online platforms.

The hyperhidrosis treatment market consists of revenues earned by entities by providing services such as microwave therapy, iontophoresis, sympathectomy, and sweat gland removal. The market value includes the value of related goods sold by the service provider or included within the service offering. The hyperhidrosis treatment market also includes sales of drysol, xerac AC, glycopyrrolate, benztropine and beta blockers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.